Introduction
Nilotinib is a tyrosine kinase inhibitor (TKI) used to treat chronic myeloid leukemia (CML) in patients who are either newly diagnosed or resistant/intolerant to other TKIs like imatinib. It targets the BCR-ABL fusion protein, which is responsible for the uncontrolled growth of leukemic cells in CML.
Uses
Nilotinib is primarily used for:
- Treatment of newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in the chronic phase.
- Treatment of chronic and accelerated phase Ph+ CML in adults who are resistant or intolerant to previous therapies including imatinib.
| Brand Name | Nilotinib |
|---|---|
| Type | |
| Weight | |
| Generic | Nilotinib |
| Manufacturer | |
| Available in | English বাংলা |
Mechanism of Action
Nilotinib inhibits the BCR-ABL tyrosine kinase, which is produced by the Philadelphia chromosome abnormality in CML. By blocking this enzyme, Nilotinib prevents the phosphorylation of proteins involved in cell proliferation, effectively halting the growth of leukemia cells. Nilotinib also inhibits other kinases like c-Kit and PDGFR, which contribute to its anticancer activity.
How Long Does It Take to Work?
Nilotinib begins working within days to weeks by reducing the number of leukemia cells in the bloodstream. However, it may take several months of continuous treatment to achieve complete cytogenetic or molecular response, which indicates full disease control.
Absorption
Nilotinib is rapidly absorbed after oral administration. However, food significantly increases its bioavailability, which is why it should be taken on an empty stomach. Peak plasma concentration is usually achieved 3 hours after dosing. Its absorption is also affected by the pH of the stomach, with higher pH reducing drug absorption.
Route of Elimination
Nilotinib is primarily metabolized in the liver by cytochrome P450 enzymes, particularly CYP3A4. It is eliminated through the feces, with only a small percentage excreted unchanged in the urine. The drug has a relatively long half-life, which allows for twice-daily dosing.
Dosage
Recommended Dose: Newly diagnosed Ph+ CML-CP: 300 mg orally twice daily.Resistant or intolerant Ph+ CML-CP and CML-AP: 400 mg orally twice daily.
Administer Nilotinib approximately 12 hours apart and must not take with food. Swallow the capsules whole with water. Do not consume food for at least 2 hours before the dose is taken and for at least one hour after. Dose adjustment may be required for hematologic and non-hematologic toxicities, and drug interactions. A lower starting dose is recommended in patients with hepatic impairment (at baseline).
The standard dosage of Nilotinib is:
- 300 mg twice daily for newly diagnosed Ph+ CML in chronic phase.
- 400 mg twice daily for chronic phase CML patients who are resistant or intolerant to prior therapy.
Administration
Nilotinib is administered orally in the form of capsules. It is typically taken twice daily, with doses separated by about 12 hours. It must be taken on an empty stomach, and patients should avoid food for at least 1 hour before and 2 hours after taking the medication. The capsules should be swallowed whole with water.
Side Effects
Common side effects of Nilotinib include:
- Nausea
- Rash
- Headache
- Fatigue
- Elevated liver enzymes
- Muscle pain
- QT prolongation (abnormal heart rhythm)
- Pancreatitis
- Severe myelosuppression (low blood cell counts)
- Hepatotoxicity (liver damage)
Toxicity
Nilotinib can cause significant toxicity, particularly QT prolongation, which can lead to potentially life-threatening arrhythmias. Other toxicities include liver damage and myelosuppression. Regular monitoring of heart function, liver enzymes, and blood counts is recommended to detect early signs of toxicity.
Precautions
Precautions include:
- Monitoring for signs of QT prolongation via ECG, particularly in patients with existing heart conditions or those on medications that affect the heart rhythm.
- Avoiding the use of strong CYP3A4 inhibitors or inducers, as they can affect the metabolism of Nilotinib .
- Regular monitoring of liver function and blood cell counts.
Interaction
Nilotinib has several drug interactions, including:
- Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) can increase Nilotinib levels, increasing the risk of toxicity.
- CYP3A4 inducers (e.g., rifampicin, phenytoin) can reduce Nilotinib levels, decreasing its effectiveness.
- Medications that prolong the QT interval (e.g., antiarrhythmic drugs) should be avoided as they may increase the risk of QT prolongation.
Disease Interaction
Nilotinib should be used cautiously in patients with:
- Cardiovascular disease, particularly those with a history of QT prolongation or arrhythmias.
- Liver disease, as Nilotinib is primarily metabolized by the liver.
- Hypokalemia or hypomagnesemia, as these conditions can exacerbate the risk of QT prolongation.
Drug Interaction
Nilotinib interacts with several medications, including:
- Antacids, which can reduce its absorption.
- CYP3A4 inhibitors and inducers, which can increase or decrease Nilotinib levels respectively.
- QT-prolonging drugs, which can increase the risk of cardiac arrhythmias.
Food Interactions
Nilotinib should not be taken with food, as food increases its absorption, which can lead to higher drug levels and increased toxicity. Patients are advised to take Nilotinib at least 1 hour before or 2 hours after a meal.
Pregnancy Use
Nilotinib is classified as Pregnancy Category D. It can cause harm to the fetus, and its use should be avoided in pregnant women unless the potential benefit outweighs the risk. Women of childbearing age should use effective contraception while on Nilotinib therapy.
Lactation Use
It is unknown whether Nilotinib is excreted in human breast milk. Due to the potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during Nilotinib therapy.
Acute Overdose
In the case of an overdose, symptoms may include severe QT prolongation, arrhythmias, and myelosuppression. Supportive care should be provided, and ECG monitoring is necessary to manage any cardiac effects. There is no specific antidote for Nilotinib overdose.
Contraindication
Nilotinib is contraindicated in patients with:
- Hypersensitivity to Nilotinib or any of its components.
- Uncorrected hypokalemia or hypomagnesemia, as these conditions increase the risk of QT prolongation.
Use Direction
Nilotinib should be taken orally, twice daily, approximately 12 hours apart. The capsules should be swallowed whole with water, and patients should avoid food for at least 1 hour before and 2 hours after taking the drug. Compliance with the dosing schedule is important to maintain effective drug levels.
Storage Conditions
Nilotinib should be stored at room temperature, between 20°C to 25°C (68°F to 77°F). It should be kept in its original packaging to protect it from moisture and light. The capsules should not be crushed or opened before taking.
Volume of Distribution
The volume of distribution (Vd) for Nilotinib is approximately 310 liters, indicating moderate tissue distribution. It is highly protein-bound (98%) in the plasma.
Half Life
The half-life of Nilotinib is approximately 17 hours, which supports its twice-daily dosing regimen.
Clearance
Nilotinib is primarily cleared through hepatic metabolism via CYP3A4, and its clearance is reduced in patients with liver impairment. Biliary and fecal excretion account for most of the drug's elimination, with only a small fraction excreted in the urine.
See in details version Nilotinib also Nilotinib in bangla
